Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Anticancer Agents Med Chem. 2013 May;13(4):563–575. doi: 10.2174/1871520611313040005

Figure 2.

Figure 2

SH-EP neuroblastoma cells were treated with a 7-mer peptide to disrupt the p53-FAK interaction and compared to untreated cells and cells treated with the TAT sequence alone. Cell viability was measured with alamarBlue® assay. There was a significant decrease in cell viability following peptide treatment compared to either control cells or cells treated with TAT sequence alone. The TAT sequence did not significantly affect cell viability.